Latest news with #LundquistInstituteforBiomedicalInnovation
Hans India
3 days ago
- Health
- Hans India
Study finds potential biomarker for long Covid
US researchers have identified a potential biomarker for long Covid that may help develop better diagnostics and potential treatments for the condition. Currently, clinicians confer a diagnosis of long Covid based upon a collection of symptoms that patients develop after SARS-CoV-2 infection. The study, reported in the journal Infection, details the detection of SARS-CoV-2 protein fragments within extracellular vesicles (EVs) -- tiny, naturally occurring packages that help cells share proteins, metabolites, and other materials. "If a patient arrives in clinic and they relate the persistence of typical signs and symptoms of long Covid, 12 weeks or more after Covid-19 infection, I give them a presumptive diagnosis, but I don't have any blood tests or biomarkers to confirm this diagnosis," said William Stringer, from the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Centre. The new biomarker could be the first specific and quantifiable indicator for confirming long Covid. The researchers collected and analysed blood samples from 14 patients over 12 weeks of aerobic exercise training (56 samples in all) in a clinical trial on long Covid. The team found 65 distinct protein fragments from SARS-CoV-2 inside the EVs. These fragments come from the virus's Pp1ab protein -- an RNA Replicase enzyme which is key to how the virus copies itself and makes other viral particles. This protein is found uniquely in SARS-CoV-2, and not in uninfected human cells, noted Asghar Abbasi, another researcher from Lundquist Institute. Significantly, the researchers found that these viral peptides were demonstrated in each subject, but not in each blood draw, in the EVs of long Covid patients and were not detected in a separate control group of pre-pandemic EV samples. Although the identified peptides originated from one of the virus's largest proteins, the researchers did not detect other comparably large proteins indicative of active viral replication. The peptides contained in the EVs may be just molecular "trash" left over after the formation of new viral proteins, they said. "We haven't run [our tests] on people without long Covid symptoms who are currently, or who were, infected with Covid," said Stringer. "This raises the question: is this just continuing to take out the trash from the Covid-infected cell, or is this really ongoing replication someplace? I think that's the mechanistic issue that needs to be resolved in future studies."
Globe and Mail
06-03-2025
- Health
- Globe and Mail
Bone and Joint Infection Market Poised for Remarkable Growth by 2032, Predicts DelveInsight
Leading the charge in the Bone and Joint Infection therapeutic landscape are industry pioneers such as Lundquist Institute for Biomedical Innovation, Debiopharm International, Sinocelltech, UCB Biopharma, Biocad, Novartis, AbbVie, University Hospital Ghent, and Suzhou Zelgen Biopharmaceuticals. DelveInsight's ' Bone and Joint Infection - Market Insight, Epidemiology, And Market Forecast - 2032 ″ report offers an in-depth understanding of the Bone and Joint Infection, historical and forecasted epidemiology as well as the Bone and Joint Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Some of the key facts of the Bone and Joint Infection Market Report: • The Bone and Joint Infection Market Size in the 7MM is expected to grow at a decent CAGR by 2032 Researchers estimate that fewer than 25 per 100K people experience osteomyelitis annually. However, studies suggest that it is much more common among hospitalized patients, with occurrences as high as 1 in every 675 hospital admissions. • The BioFire Joint Infection Panel (JI panel) received FDA approval in 2022 as a multiplex PCR assay designed to detect common bone and joint pathogens. The panel targeted 39 pathogens, including select Gram-positive and Gram-negative bacteria, yeast, and antimicrobial resistance genes. • A performance evaluation of the JI panel was conducted using 63 frozen, residual joint fluid specimens retrospectively and 104 de-identified specimens prospectively tested within one week of collection. • Key drugs in the Bone and Joint Infection market: Afabicin, Omadacycline Pill, SCT650C, Bimekizumab, Secukinumab, Upadacitinib, Jaktinib, Filgotinib, Ixekizumab, and others. • Key companies in the Bone and Joint Infection market: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Debiopharm International SA, Sinocelltech Ltd., UCB Biopharma SRL, Biocad, Novartis Pharmaceuticals, AbbVie, University Hospital Ghent, Suzhou Zelgen Biopharmaceuticals Co., Ltd., Tasly Pharmaceutical Group Co., Ltd., Asia Cell Therapeutics (Shanghai) Co., Ltd., Akeso, Alfasigma S.p.A., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Eli Lilly and Company, and others. To Know in detail about the Bone and Joint Infection market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Bone and Joint Infection Market Forecast Bone and Joint Infection Overview Bone and Joint Infections are serious infections that affect bones (osteomyelitis) and joints (septic arthritis), often caused by bacterial pathogens such as Staphylococcus aureus and Streptococcus species. These infections can result from direct contamination through surgery or injury, bloodstream infections, or the spread of nearby infections. BJIs are particularly concerning in immunocompromised individuals, those with diabetes, and patients with implanted prosthetic joints. Early diagnosis and prompt treatment are crucial to prevent complications such as bone destruction, chronic infection, and joint dysfunction. Standard treatment includes prolonged antibiotic therapy and, in severe cases, surgical intervention to remove infected tissue. Advances in diagnostics, antimicrobial treatments, and surgical techniques continue to improve patient outcomes, making the Bone and Joint Infection market a key area of focus for medical research and pharmaceutical development. Bone and Joint Infection Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Download the report to understand which factors are driving Bone and Joint Infection epidemiology trends @ Bone and Joint Infection Epidemiology Forecast Bone and Joint Infection Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bone and Joint Infection market or expected to be launched during the study period. The analysis covers the Bone and Joint Infection market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Bone and Joint Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Bone and Joint Infection Market Strengths • Ongoing research and development of novel antibiotics and surgical techniques are improving treatment outcomes for bone and joint infections. • Increased awareness among healthcare providers and advancements in diagnostic tools are leading to earlier detection and better management of infections. Bone and Joint Infection Market Weaknesses • The rise of multidrug-resistant bacterial strains limits effective treatment options, making management more complex. • Surgical interventions, long-term antibiotic therapy, and hospitalization expenses make treatment financially burdensome for patients and healthcare systems. Scope of the Bone and Joint Infection Market Report • Study Period: 2019–2032 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Bone and Joint Infection Companies: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Debiopharm International SA, Sinocelltech Ltd., UCB Biopharma SRL, Biocad, Novartis Pharmaceuticals, AbbVie, University Hospital Ghent, Suzhou Zelgen Biopharmaceuticals Co., Ltd., Tasly Pharmaceutical Group Co., Ltd., Asia Cell Therapeutics (Shanghai) Co., Ltd., Akeso, Alfasigma S.p.A., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Eli Lilly and Company, and others. • Key Bone and Joint Infection Therapies: Afabicin, Omadacycline Pill, SCT650C, Bimekizumab, Secukinumab, Upadacitinib, Jaktinib, Filgotinib, Ixekizumab, and others. • Bone and Joint Infection Therapeutic Assessment: Bone and Joint Infection currently marketed and Bone and Joint Infection emerging therapies • Bone and Joint Infection Market Dynamics: Bone and Joint Infection market drivers and Bone and Joint Infection market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Bone and Joint Infection Unmet Needs, KOL's views, Analyst's views, Bone and Joint Infection Market Access and Reimbursement To learn more about the key players and advancements in the Bone and Joint Infection Treatment Landscape, visit the Table of Contents 1. Bone and Joint Infection Market Report Introduction 2. Executive Summary for Bone and Joint Infection 3. SWOT analysis of Bone and Joint Infection 4. Bone and Joint Infection Patient Share (%) Overview at a Glance 5. Bone and Joint Infection Market Overview at a Glance 6. Bone and Joint Infection Disease Background and Overview 7. Bone and Joint Infection Epidemiology and Patient Population 8. Country-Specific Patient Population of Bone and Joint Infection 9. Bone and Joint Infection Current Treatment and Medical Practices 10. Bone and Joint Infection Unmet Needs 11. Bone and Joint Infection Emerging Therapies 12. Bone and Joint Infection Market Outlook 13. Country-Wise Bone and Joint Infection Market Analysis (2019–2032) 14. Bone and Joint Infection Market Access and Reimbursement of Therapies 15. Bone and Joint Infection Market Drivers 16. Bone and Joint Infection Market Barriers 17. Bone and Joint Infection Appendix 18. Bone and Joint Infection Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
